(Reuters) – British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmune liver disease. The drug resulted in an improvement in itch compared to a placebo, GSK said. Cholestatic pruritus, also known as relentless […]
Health
GSK drug meets main goal in late-stage study to treat relentless itch
Audio By Carbonatix
(Reuters) – British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmune liver disease.
The drug resulted in an improvement in itch compared to a placebo, GSK said.
Cholestatic pruritus, also known as relentless itch, is one of the most common symptoms of primary biliary cholangitis, an autoimmune disease that can lead to liver failure, the drugmaker said.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Abinaya Vijayaraghavan)